;redcap_repeat_instrument;line_number;line_indication;CIAH;associated_chip;chemotherapy_type;targeted_therapy_type;immunotherapy_type;first_dose_date;last_dose_date;stop_chemotherapy_cause;neurotoxicity;progression_date;progression_type;chemotherapy_RECIST_response;PFS;cell_line_code;date_cell_line
1;ligne_mtastatique_de_traitement;1.0;induction_or_perioperative;0.0;0.0;folfirinox;none;none;2020-07-29;2021-01-28;"curative;maintenance";grade_2;2021-04-28;progression_metastasis;partial_response;9.0;GR0069;2023-05-25
2;ligne_mtastatique_de_traitement;1.0;induction_or_perioperative;0.0;0.0;folfiri;bevacizumab;none;2020-12-30;2021-05-05;"progression;instensification";grade_0;2021-04-28;progression_metastasis;partial_response;3.9;GR0069;2023-05-25
3;ligne_mtastatique_de_traitement;2.0;intensification;1.0;0.0;folfirinox;bevacizumab;none;2021-09-30;2022-01-13;progression;grade_1;2022-01-18;progression_metastasis;stable_disease;3.6;GR0069;2023-05-25
4;ligne_mtastatique_de_traitement;3.0;metastatic;0.0;0.0;folfiri3;aflibercept;none;2022-01-26;2022-03-23;"progression;AEG";grade_1;2022-04-01;progression_metastasis;progressive_disease;2.1;GR0069;2023-05-25
5;hai_chemotherapy;;;;;"oxaliplatine;folfiri";bevacizumab;;2021-06-25;2021-08-06;;;2021-08-31;;stable_disease;;GR0069;2023-05-25
